[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"schizophrenia--schizoaffective-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:schizophrenia--schizoaffective-disorder":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,60,88,109,134,167],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100642980","feel-good-a-multicenter-trial-of-a-mindfulness-based-group-therapy-in-young-adults-with-early-psychosis-100642980",false,"NCT07645443","FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis","Mindfulness-based Group Therapy in Young Inpatients With Acute Early Psychosis (FEEL-GOOD)","FEEL-GOOD","Inclusion Criteria:\n\n* Age 16 to 35 years\n* Clinical diagnosis of early psychosis, defined as first psychotic episode within the last 5 years as assessed with the Structural Clinical Interview for DSM-5 Research Version (SCID-5-RV)\n* DSM-5 schizophrenia spectrum or other psychotic disorder confirmed with SCID-5-RV (DSM-5: 297.1, 298.8, 295.4, 295.9, 295.7, 298.8, 298.9) Currently receiving inpatient\u002Fday clinic treatment with a planned stay of at least 4 weeks\n* Interested in and willing to participate in FEEL-GOOD and\u002For TAU.\n\nExclusion Criteria:\n\n* Insufficient German language abilities\n* Acute suicidality or acute threat to others","ALL","16 Years","35 Years",{"count":21,"type":22},252,"ESTIMATED","INTERVENTIONAL",[25],"NA","FEEL-GOOD is a prospective multi-site single-blinded randomized controlled trial in young inpatients with acute early psychosis. Participants are randomized 1:1 to FEEL-GOOD plus treatment as usual (TAU) or TAU alone. The intervention consists of one individual preparatory session and eight modularized group sessions delivered over four weeks involving four to eight participants at each session and including practice and homework tasks. Outcomes are assessed at baseline, 4 weeks post-intervention, and 6 months follow-up, with the primary outcome being observer-rated total psychopathology as measured with the assessed by the total score of the Positive and Negative Syndrome Scale (PANSS) post-treatment (4 weeks post baseline).",[28,29,30,31,32],"Delusional Disorder","Brief Psychotic Disorder","Schizophreniform Disorder","Schizophrenia \u002F Schizoaffective Disorder","Other Psychotic Disorder Not Due to A Substance or Known Physiological Condition",[34,35,36,37,38,39,40,41,42,43,44,45,46],"Randomized controlled trial","Emotion regulation","Ecological momentary assessment","Early psychosis","First-episode psychosis","EMA","Schizophrenia spectrum disorder","Psychosis","Mindfulness","Mindfulness-based Interventions","Schizophrenia","Schizoaffective disorder","Delusional disorder","RECRUITING","2026-07-14",{"date":50,"type":51},"2026-07-15","ACTUAL",{"date":53,"type":51},"2026-05-27",{"date":55,"type":22},"2028-12-31",{"name":57,"class":58},"Stephanie Mehl","OTHER",8,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":17,"minAge":67,"maxAge":4,"enrollmentInfo":68,"targetDuration":4,"studyType":23,"phases":70,"briefSummary":71,"conditions":72,"keywords":73,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":4},"100647419","healing-stigma-through-stories-100647419","NCT07708402","Healing Stigma Through Stories","Healing Stigma Through Stories: Learning From International Practices to Develop and Evaluate a Narrative Program for Individuals With Schizophrenia","Inclusion Criteria:\n\n* Aged 18 years or older.\n* Diagnosed with schizophrenia or schizoaffective disorder.\n* Clinically stable at the time of study enrollment.\n* Able to communicate in Mandarin Chinese or Taiwanese.\n* Able to read and write and complete study questionnaires.\n\nExclusion Criteria:\n\n* Individuals who lack the capacity to provide informed consent. Decision-making capacity will be assessed using a 10-item true\u002Ffalse questionnaire adapted from Okoli et al. (2018). Participants who answer fewer than 7 questions correctly will be excluded. Those who answer 7 or more questions correctly will receive an additional explanation from the research team. Only individuals who demonstrate a complete understanding of the study after this explanation will be enrolled.\n* Unwilling to have the intervention sessions audio-recorded.","18 Years",{"count":69,"type":22},24,[25],"This study is the first phase of the research project. The purpose of this phase is to develop and refine a narrative-based intervention designed to reduce self-stigma among people with schizophrenia.\n\nA small pilot study will be conducted with 24 participants recruited from halfway houses in northern Taiwan. Eligible participants will receive the intervention, which consists of four group sessions and four individual sessions, held once a week for a total of eight weeks. The program uses narrative therapy techniques to help participants explore their personal experiences and reduce self-stigma. Participants will complete a workbook during the program, and the written content will be analyzed to better understand their experiences with stigma. Any personal information will be removed to protect participants' privacy. Before and after the intervention, participants will complete questionnaires on self-stigma, depression, social functioning, well-being, hope, and recovery. Information on medication use will also be collected. Group and individual sessions will be audio-recorded for research purposes. The questionnaire data and recordings will be used to evaluate the feasibility and preliminary effects of the intervention.",[31],[74,75,76,77],"schizophrenia","mix-method study","self-stigma","narrative therapy","NOT_YET_RECRUITING","2026-07-10",{"date":81,"type":51},"2026-07-16",{"date":83,"type":22},"2026-08-01",{"date":85,"type":22},"2027-07",{"name":87,"class":58},"National Yang Ming Chiao Tung University",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":67,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":23,"phases":97,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":108},"100646151","the-effect-of-structured-medical-nutrition-therapy-on-systemic-inflammation-index-in-patients-with-schizophrenia-receiving-antipsychotic-therapy-100646151","NCT07696000","The Effect of Structured Medical Nutrition Therapy on Systemic Inflammation Index in Patients With Schizophrenia Receiving Antipsychotic Therapy","Inclusion Criteria:\n\nAdults aged 18-60 years. Diagnosed with schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).\n\nReceiving stable antipsychotic therapy for at least 4 weeks before enrollment. Hospitalized at Prof. Dr. M. Ildrem Psychiatric Hospital during the study period.\n\nAble to consume an oral diet. Willing to participate and provide written informed consent (or consent provided by a legally authorized representative when applicable).\n\nExclusion Criteria:\n\nAcute infection, autoimmune disease, malignancy, or other inflammatory conditions that may influence the Systemic Inflammation Index (SII).\n\nChronic liver disease, end-stage renal disease, or severe heart failure. Pregnancy or breastfeeding. Current use of systemic corticosteroids, immunosuppressive agents, or anti-inflammatory medications that could affect inflammatory biomarkers.\n\nReceiving enteral or parenteral nutrition. Participation in another interventional clinical trial within the previous 3 months.\n\nIncomplete clinical or laboratory data. Inability to complete the intervention or follow-up assessments.","60 Years",{"count":96,"type":22},100,[25],"Patients with schizophrenia receiving long-term antipsychotic therapy are at increased risk of chronic low-grade inflammation and metabolic disturbances, which contribute to poor physical health outcomes and increased cardiovascular morbidity. Structured Medical Nutrition Therapy (MNT), consisting of individualized nutrition assessment, dietary intervention, nutrition education, and regular monitoring, has the potential to improve dietary quality and modulate systemic inflammation. This study aims to evaluate the effect of Structured Medical Nutrition Therapy on the Systemic Inflammation Index (SII), a novel inflammatory biomarker derived from neutrophil, lymphocyte, and platelet counts, in patients with schizophrenia receiving antipsychotic therapy. It is hypothesized that patients receiving structured MNT will demonstrate a greater reduction in SII compared with those receiving standard nutritional care, supporting the integration of evidence-based nutritional interventions into the comprehensive management of schizophrenia to improve metabolic and inflammatory outcomes.",[31],"2026-07-05",{"date":79,"type":51},{"date":103,"type":51},"2026-07-01",{"date":105,"type":22},"2026-10-30",{"name":107,"class":58},"DINA KEUMALA SARI",1,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":67,"maxAge":94,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":121,"conditions":122,"keywords":123,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":108},"100644968","phase-1-a-cognitive-mobile-intervention-for-motivation-in-psychotic-disorders-100644968","NCT07674914","A Cognitive Mobile Intervention for Motivation in Psychotic Disorders","A User-Informed Digital Therapeutic for Specific Cognitive Disabilities to Improve Mental Health in Schizophrenia and Related Mental Illnesses","Inclusion Criteria:\n\n* diagnosis of schizophrenia, schizoaffective disorder, or a related psychotic disorder\n* own a smartphone\n* English speaking\n* experiencing challenges with cognitive functioning\n* no changes to antipsychotic medication in past month\n\nExclusion Criteria:\n\n* history of neurological disorder\n* traumatic brain injury with loss of consciousness \\> 10 minutes or behavioral sequelae.",{"count":117,"type":22},45,[119,120],"PHASE1","PHASE2","The goal of this study is to develop and test the impact of a smartphone-based working memory cognitive training digital therapeutic for individuals with schizophrenia or a related disorder.",[31],[74,124],"psychosis","2026-06-23",{"date":127,"type":51},"2026-06-30",{"date":129,"type":22},"2026-09",{"date":131,"type":22},"2028-08",{"name":133,"class":58},"University of Alabama at Birmingham",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":17,"minAge":67,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":146,"conditions":147,"keywords":148,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":166},"100640709","nst-spark-open-label-phase-1-sttr-ignite-100640709","NCT07593456","NST-SPARK Open-Label Phase 1 STTR (IGNITE)","Investigating a Gamified NegatIve-symptom Therapeutic Based on Evidence-based Cognitive Therapy (IGNITE)","IGNITE","Inclusion Criteria:\n\n* Age 18-65 years\n* Diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder or unspecified psychotic disorder\n* Clinically stable, defined as no acute positive psychotic symptom exacerbation or recent hospitalization or medication changes within the last month.\n* Moderate to severe negative symptoms: CAINS MAP subscale \\>17 (28).\n* Sufficient functioning and capacity to consent and participate in a longitudinal study.\n* Actively engaged in outpatient treatment.\n* Able and willing to use a smartphone and maintain internet connection during use (through wifi or data plan).\n\nExclusion Criteria:\n\n* Safety risk (e.g., suicide attempt or homicidal ideation within 12 weeks)\n* Issues that prevent subject from using the smartphone app: e.g., hearing, vision, or other relevant physical disability\n* IQ \\\u003C 70 based on clinical and historical information\n* Cognitive impairment limiting engagement in study\n* Prominent mood symptoms as defined by active manic, hypomanic or depressive episode.\n* Has previously undergone cognitive behavioral therapy for psychosis or recovery-oriented cognitive therapy for negative symptoms.","65 Years",{"count":144,"type":22},30,[25],"Schizophrenia Spectrum disorders (SSD) are among the most devastating psychiatric disorders. Prominent negative symptoms such as low motivation, anhedonia, asociality, and emotional flattening are experienced by up to 60% of individuals with SSD and are often considered to be the greatest contributors to functional disability. Currently, there are no FDA-approved or cleared medications or therapeutics targeting negative symptoms of schizophrenia. In this phase I proposal, North Shore Therapeutics (NST) is collaborating with the Feinstein Institutes of Medical Research (FIMR; Northwell Health) and the University of Pennsylvania (Penn) to develop a novel augmented reality (AR) therapeutic (NST-SPARK) targeting negative symptoms in individuals with SSD. NST-SPARK is a smartphone application that delivers Recovery-oriented Cognitive Therapy (CT-R) via gamified AR experiences to provide experiential learning that dismantles maladaptive beliefs. Preliminary findings suggest that this approach is feasible, acceptable, and may reduce defeatist beliefs associated with negative symptoms. NST-SPARK v.2.0 is being developed in partnership with a lived experience advisory panel. NST-SPARK v2.0 will deliver a 12-week course of treatment and will be developed over 10 development sprints spanning 9 months. In the second phase, the investigators will introduce NST-SPARK v2.0 to individuals with SSD (n=30) and moderate to severe negative symptoms for 12 weeks in a single-arm open-label study. The primary outcome is the efficacy of NST-SPARK v.2.0 in reducing experiential negative symptoms. Secondary outcomes include efficacy in reducing defeatist beliefs; efficacy in improving functioning; user statistics quantifying adherence to the prescribed sessions; qualitative, semi-structured feedback to guide future product development. This study will set the stage for FDA-informed phase II trials.",[31],[74,149,150,151,152,153,154,155],"recovery-oriented cognitive therapy (CT-R)","cognitive behavioral therapy (CBT)","prescription digital therapeutic","software as a medical device (SaMD)","augmented reality (AR)","negative symptoms","avolition","2026-05-13",{"date":158,"type":51},"2026-05-18",{"date":160,"type":22},"2027-03-01",{"date":162,"type":22},"2028-08-31",{"name":164,"class":165},"North Shore Therapeutics, Inc.","INDUSTRY",2,{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":67,"maxAge":94,"enrollmentInfo":173,"targetDuration":4,"studyType":175,"phases":4,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":108},"100374761","brain-imaging-of-cognition-inn-schizophrenia-and-depression-100374761","NCT04159662","Brain Imaging of Cognition Inn Schizophrenia and Depression","Inclusion Criteria:\n\n* age 18-60 years\n* current Intelligence Quotient (IQ) \\> 70 as measured by the Wechsler Abbreviated Scale of Intelligence (WASI)\n* the ability to read and speak fluent English\n* a diagnosis of schizophrenia, schizoaffective or major depression disorder\n* stable medication for more than one month\n\nExclusion Criteria:\n\n* significant neurological or other medical disorders that may produce cognitive impairment\n* a recent history of substance abuse or dependence (within the past 3 months)\n* any magnetic resonance imaging (MRI) contraindications (e.g. metallic head implant, history of seizure, pacemaker)\n* decisional incapacity requiring a guardian\n* taking medications that are rated as Anticholinergic Burden (ACB) Score 3 (severe) or taking benzodiazepines on a daily basis\n* Finally, participants could not be severely symptomatic at the time of study enrolment to ensure that they could understand and complete all study assessments. This criterion was defined as a score ≤34 on the Montgomery-Åsberg Depression Rating Scale (MADRS; Montgomery \\& Åsberg, 1979) for the MDD group and a score ≤95 on the Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987) for the SZ group.",{"count":174,"type":22},90,"OBSERVATIONAL","Schizophrenia and depression are among the most disabling disorders in all of medicine. Cognitive deficits play a key role in patients' disability, affecting their capacity to contribute actively to society by sustaining employment or academic activity. Moreover, cognitive difficulties tend to persist even after the stabilization of other clinical symptoms. Verbal memory and emotion regulation are two important cognitive domains that are impaired in schizophrenia and depression and are associated with patients' functional outcomes. In this study, brain imaging is used to investigate the brain mechanisms underlying these cognitive deficits in these populations.",[31,178],"Depression \u002F Major Depressive Disorder","2026-03-19",{"date":181,"type":51},"2026-03-23",{"date":183,"type":51},"2019-12-12",{"date":185,"type":22},"2026-10-01",{"name":187,"class":58},"The Royal Ottawa Mental Health Centre"]